Redmile Group, LLC 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Redmile Group, LLC disclosed 62 US equity positions worth $1.4bn in its Q4 2024 13F filing. The largest position was SRRK at 13.7% of the reported book, followed by KRYS and NRIX. Against the Q3 2024 filing, it opened 1 new position, added to 9 and reduced 34 among the top 50 holdings.
What did Redmile Group, LLC own in Q4 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 13.7% | $196.6m | 4,549,881 | -13% | reduced |
| 2 | KRYS KRYSTAL BIOTECH INC | Healthcare | 8.2% | $118.0m | 753,175 | -7% | reduced |
| 3 | NRIX NURIX THERAPEUTICS INC | Healthcare | 5.5% | $79.0m | 4,192,627 | -2% | reduced |
| 4 | ZYME ZYMEWORKS INC | Healthcare | 4.9% | $70.9m | 4,840,463 | -5% | reduced |
| 5 | AM6 AMICUS THERAPEUTICS INC | 4.6% | $66.5m | 7,054,890 | -14% | reduced | |
| 6 | REPL REPLIMUNE GROUP INC | Healthcare | 4.1% | $59.4m | 4,905,527 | 3% | added |
| 7 | IMNM IMMUNOME INC | Healthcare | 3.6% | $51.3m | 4,828,026 | -1% | reduced |
| 8 | STOK STOKE THERAPEUTICS INC | Healthcare | 3.5% | $50.7m | 4,593,629 | -3% | reduced |
| 9 | LIVN LIVANOVA PLC | Healthcare | 3.4% | $48.3m | 1,043,539 | 19% | added |
| 10 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 3.1% | $44.3m | 1,100,432 | -21% | reduced |
| 11 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 2.7% | $38.1m | 2,895,478 | -9% | reduced |
| 12 | BEAM BEAM THERAPEUTICS INC | Healthcare | 2.6% | $37.9m | 1,528,567 | -5% | reduced |
| 13 | RGNX REGENXBIO INC | Healthcare | 2.6% | $37.1m | 4,794,780 | -2% | reduced |
| 14 | AKERO THERAPEUTICS INC | 2.4% | $34.4m | 1,235,209 | -11% | reduced | |
| 15 | BHVN BIOHAVEN LTD | Healthcare | 2.4% | $33.8m | 904,496 | -13% | reduced |
| 16 | ANNX ANNEXON INC | Healthcare | 2.3% | $32.3m | 6,300,644 | -2% | reduced |
| 17 | ADCT ADC THERAPEUTICS SA | Healthcare | 2.2% | $31.2m | 15,666,731 | -0% | held |
| 18 | NGNE NEUROGENE INC | 2.1% | $30.2m | 1,319,763 | 37% | added | |
| 19 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 1.9% | $27.9m | 312,683 | -5% | reduced |
| 20 | COGT COGENT BIOSCIENCES INC | Healthcare | 1.9% | $27.7m | 3,554,836 | -21% | reduced |
| 21 | ABSI ABSCI CORPORATION | 1.5% | $21.6m | 8,253,316 | 0% | held | |
| 22 | FATE FATE THERAPEUTICS INC | Healthcare | 1.5% | $21.2m | 12,872,946 | -2% | reduced |
| 23 | 1K0 IGM BIOSCIENCES INC | 1.3% | $18.0m | 2,952,131 | -4% | reduced | |
| 24 | ETNBGBP 89BIO INC | 1.2% | $16.9m | 2,167,176 | 38% | added | |
| 25 | SLN SILENCE THERAPEUTICS PLC | 1.2% | $16.5m | 2,399,317 | 26% | added | |
| 26 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.1% | $15.9m | 619,300 | -9% | reduced |
| 27 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.1% | $15.6m | 615,775 | -6% | reduced |
| 28 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 1.0% | $14.7m | 320,149 | 22% | added |
| 29 | IMVT IMMUNOVANT INC | Healthcare | 1.0% | $14.2m | 571,824 | -11% | reduced |
| 30 | CBLL CERIBELL INC | 0.8% | $11.3m | 435,239 | – | new | |
| 31 | SYK STRYKER CORPORATION | Healthcare | 0.8% | $11.0m | 30,676 | -6% | reduced |
| 32 | RAPT THERAPEUTICS INC | 0.7% | $10.2m | 6,475,317 | 1183% | added | |
| 33 | BNTX BIONTECH SE | Healthcare | 0.7% | $9.5m | 83,471 | -46% | reduced |
| 34 | ISRG INTUITIVE SURGICAL INC | Healthcare | 0.6% | $8.8m | 16,943 | -37% | reduced |
| 35 | KROS KEROS THERAPEUTICS INC | Healthcare | 0.6% | $8.7m | 552,506 | 0% | held |
| 36 | NUVB NUVATION BIO INC | Healthcare | 0.6% | $8.1m | 3,031,009 | 0% | held |
| 37 | ARDX ARDELYX INC | Healthcare | 0.6% | $8.0m | 1,576,259 | -5% | reduced |
| 38 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.6% | $8.0m | 411,728 | 0% | held |
| 39 | VERVE THERAPEUTICS INC | 0.5% | $7.4m | 1,318,164 | -5% | reduced | |
| 40 | STTK SHATTUCK LABS INC | Healthcare | 0.5% | $6.7m | 5,539,724 | -1% | reduced |
| 41 | FDMT 4D MOLECULAR THERAPEUTICS IN | 0.5% | $6.7m | 1,196,910 | -5% | reduced | |
| 42 | ALXO ALX ONCOLOGY HLDGS INC | Healthcare | 0.4% | $6.2m | 3,689,611 | -4% | reduced |
| 43 | PEN PENUMBRA INC | Healthcare | 0.4% | $6.1m | 25,743 | 86% | added |
| 44 | PRME PRIME MEDICINE INC | 0.4% | $6.1m | 2,074,350 | 0% | held | |
| 45 | ATRA ATARA BIOTHERAPEUTICS INC | 0.4% | $5.9m | 441,701 | -2% | reduced | |
| 46 | CYTK CYTOKINETICS INC | Healthcare | 0.3% | $4.4m | 92,598 | -5% | reduced |
| 47 | STXS STEREOTAXIS INC | 0.3% | $4.1m | 1,799,465 | -15% | reduced | |
| 48 | ALLKGUSD ALLAKOS INC | 0.3% | $3.6m | 3,015,097 | -2% | reduced | |
| 49 | CATBUSD ASTRIA THERAPEUTICS INC | 0.2% | $3.1m | 346,278 | 11% | added | |
| 50 | ACIU AC IMMUNE SA | Healthcare | 0.2% | $2.8m | 1,034,299 | -39% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.